Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products

Basel Assaf, Laurence O. Whiteley

Research output: Contribution to journalArticle

Abstract

Progress in understanding the molecular bases of human health and disease in recent decades has flourished making it possible for the field of gene therapy (GT) to offer new possibilities for treating, and even curing, a plethora of medical conditions such as monogenic disorders and metabolic diseases. GT is a therapeutic intervention to genetically alter or modify living cells by means of gene delivery achieved using either viral vectors or nonviral vectors, with adeno-associated virus (AAV) vectors constituting market-share majority. Although GT is conceptually attractive, adverse and even fatal iatrogenic complications have marred the initial enthusiasm of clinical successes. The properties of investigational AAV-based GT may pose safety concerns unique from those of small molecule drugs and other macromolecular biologics, such as ectopic or unregulated expression of the transgene, long-term persistence, and off-target distribution. Herein, we discuss considerations in the design of a comprehensive preclinical safety program for AAV-based GT prior to administration in humans.

Original languageEnglish (US)
Pages (from-to)1020-1027
Number of pages8
JournalToxicologic Pathology
Volume46
Issue number8
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Gene therapy
Dependovirus
Viruses
Genetic Therapy
Safety
Metabolic Diseases
Biological Products
Transgenes
Curing
Genes
Cells
Health
Molecules
Pharmaceutical Preparations

Keywords

  • AAV
  • adeno-associated virus
  • gene therapy
  • preclinical
  • study design

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Toxicology
  • Cell Biology

Cite this

Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products. / Assaf, Basel; Whiteley, Laurence O.

In: Toxicologic Pathology, Vol. 46, No. 8, 01.12.2018, p. 1020-1027.

Research output: Contribution to journalArticle

Assaf, Basel ; Whiteley, Laurence O. / Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products. In: Toxicologic Pathology. 2018 ; Vol. 46, No. 8. pp. 1020-1027.
@article{505d6ab3b2e0414aaec9ac0317f0a099,
title = "Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products",
abstract = "Progress in understanding the molecular bases of human health and disease in recent decades has flourished making it possible for the field of gene therapy (GT) to offer new possibilities for treating, and even curing, a plethora of medical conditions such as monogenic disorders and metabolic diseases. GT is a therapeutic intervention to genetically alter or modify living cells by means of gene delivery achieved using either viral vectors or nonviral vectors, with adeno-associated virus (AAV) vectors constituting market-share majority. Although GT is conceptually attractive, adverse and even fatal iatrogenic complications have marred the initial enthusiasm of clinical successes. The properties of investigational AAV-based GT may pose safety concerns unique from those of small molecule drugs and other macromolecular biologics, such as ectopic or unregulated expression of the transgene, long-term persistence, and off-target distribution. Herein, we discuss considerations in the design of a comprehensive preclinical safety program for AAV-based GT prior to administration in humans.",
keywords = "AAV, adeno-associated virus, gene therapy, preclinical, study design",
author = "Basel Assaf and Whiteley, {Laurence O.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1177/0192623318803867",
language = "English (US)",
volume = "46",
pages = "1020--1027",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products

AU - Assaf, Basel

AU - Whiteley, Laurence O.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Progress in understanding the molecular bases of human health and disease in recent decades has flourished making it possible for the field of gene therapy (GT) to offer new possibilities for treating, and even curing, a plethora of medical conditions such as monogenic disorders and metabolic diseases. GT is a therapeutic intervention to genetically alter or modify living cells by means of gene delivery achieved using either viral vectors or nonviral vectors, with adeno-associated virus (AAV) vectors constituting market-share majority. Although GT is conceptually attractive, adverse and even fatal iatrogenic complications have marred the initial enthusiasm of clinical successes. The properties of investigational AAV-based GT may pose safety concerns unique from those of small molecule drugs and other macromolecular biologics, such as ectopic or unregulated expression of the transgene, long-term persistence, and off-target distribution. Herein, we discuss considerations in the design of a comprehensive preclinical safety program for AAV-based GT prior to administration in humans.

AB - Progress in understanding the molecular bases of human health and disease in recent decades has flourished making it possible for the field of gene therapy (GT) to offer new possibilities for treating, and even curing, a plethora of medical conditions such as monogenic disorders and metabolic diseases. GT is a therapeutic intervention to genetically alter or modify living cells by means of gene delivery achieved using either viral vectors or nonviral vectors, with adeno-associated virus (AAV) vectors constituting market-share majority. Although GT is conceptually attractive, adverse and even fatal iatrogenic complications have marred the initial enthusiasm of clinical successes. The properties of investigational AAV-based GT may pose safety concerns unique from those of small molecule drugs and other macromolecular biologics, such as ectopic or unregulated expression of the transgene, long-term persistence, and off-target distribution. Herein, we discuss considerations in the design of a comprehensive preclinical safety program for AAV-based GT prior to administration in humans.

KW - AAV

KW - adeno-associated virus

KW - gene therapy

KW - preclinical

KW - study design

UR - http://www.scopus.com/inward/record.url?scp=85058731014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058731014&partnerID=8YFLogxK

U2 - 10.1177/0192623318803867

DO - 10.1177/0192623318803867

M3 - Article

C2 - 30295175

AN - SCOPUS:85058731014

VL - 46

SP - 1020

EP - 1027

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

IS - 8

ER -